Senate Generic Reform Bill Likely To Result In Earlier ANDA Filings
This article was originally published in The Tan Sheet
A bipartisan Senate bill would encourage earlier ANDA filings by generics firms to head off new innovator patent listings and secure sole rights to 180-day exclusivity
You may also be interested in...
An appeals court's dismissal of Apotex' lawsuit against FDA relating to patent listings affirms a key provision in the final rule reforming Hatch/Waxman
Patent declaration forms must be used for Orange Book submission of patent information under FDA's generic reform final rule
The Generic Pharmaceutical Association appears confident it will not have to make significant concessions to move S 812 through the House